<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiplatelet agents are administered in the treatment of a large number of <z:e sem="disease" ids="C0277562" disease_type="Disease or Syndrome" abbrv="">adult diseases</z:e>: <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> with their thromboembolic complications, primary and secondary prevention </plain></SENT>
<SENT sid="1" pm="."><plain>In childhood however, the situation is substantially different </plain></SENT>
<SENT sid="2" pm="."><plain>The lack of large interventional trials on the use of antiplatelet drugs in children, has led to greater uncertainty, and a less extensive use of these drugs, limited to fewer indications </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this article was to review the studies conducted to date on the use of antiplatelet agents in children </plain></SENT>
<SENT sid="4" pm="."><plain>A concerted effort has been made to identify which are the shared therapeutic indications of this class of compounds, the recommended dose, the contraindications and the possible side effects </plain></SENT>
<SENT sid="5" pm="."><plain>In brief, an attempt has been made to ascertain the interesting potential of these drugs which are so often neglected in children </plain></SENT>
</text></document>